In patients with major depressive disorder (MDD) and general medical conditions, the use of antidepressants was safe and effective compared to patients without such conditions. Combination therapy was no different than monotherapy, regardless of the number of comorbidities present, according to the recent findings of a new randomized, single-blind, placebo-controlled trial published in The Annals of Family Medicine.
In patients with major depressive disorder (MDD) and general medical conditions, the use of antidepressants was safe and effective compared to patients without such conditions. Combination therapy was no different than monotherapy, regardless of the number of comorbidities present, according to the recent findings of a new randomized, single-blind, placebo-controlled trial published in The Annals of Family Medicine.
In this trial, called CO-MED (Combining Medications to Enhance Depression Outcomes), researchers randomly assigned patients to receive escitalopram + placebo, bupropion-SR + escitalopram, or venlafaxine-XR + mirtazapine. Patients had to be diagnosed with recurrent or chronic non-psychotic MDD with the index episode lasting ≥2 months and score of at least 16 on the 17-item Hamilton Rating Scale for Depression. General medical conditions were self-reported and included if the condition was currently being treated and medically stable per the primary physician. Patients were stratified by the number of conditions present (0, 1, 2, or ≥3) and comparisons were made to patients without such conditions. Analyses were adjusted for treatment, age, education, employment, age at first episode, body mass index, and systolic blood pressure.
A total of 665 patients were enrolled and the majority reported no medical conditions (49.5%), followed by 1 (23.8%), 2 (14.8%), and ≥3 conditions (11.9%). After adjustment for confounders, patients with ≥3 conditions had an increased odds of impaired social and occupational function at 12 weeks [adjusted odds ratio (AOR)=2.17; P<.0083] but not at 28 weeks [AOR=1.49; P=.48]. No differences in symptom severity or tolerability were seen between the groups. There were no statistically significant differences in early termination, remission, response, or tolerability between the treatment groups regardless of the number of general medical conditions.
Researchers noted several study limitations including limited statistical power to detect differences between medical condition groups and their self-reported nature, exclusion of patients with unstable or untreated medical conditions, and use of FDA-approved dosing as higher dosing could lead to a different response.
This trial was funded by the National Institute of Mental Health.
SOURCE
Morris DW, Budhwar N, Husain M, et al. Depression treatment in patients with general medical conditions: Results from the CO-MED trial. Annals of Family Medicine. 2012;10:23–33.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.